These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 9368023)
1. Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2. Bourgeois L; Brillard-Bourdet M; Deperthes D; Juliano MA; Juliano L; Tremblay RR; Dubé JY; Gauthier F J Biol Chem; 1997 Nov; 272(47):29590-5. PubMed ID: 9368023 [TBL] [Abstract][Full Text] [Related]
2. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. Charlesworth MC; Young CY; Miller VM; Tindall DJ J Androl; 1999; 20(2):220-9. PubMed ID: 10232657 [TBL] [Abstract][Full Text] [Related]
3. Kininogen-derived fluorogenic substrates for investigating the vasoactive properties of rat tissue kallikreins--identification of a T-kinin-releasing rat kallikrein. El Moujahed A; Brillard-Bourdet M; Juliano MA; Moreau T; Chagas JR; Gutman N; Prado ES; Gauthier F Eur J Biochem; 1997 Jul; 247(2):652-8. PubMed ID: 9266709 [TBL] [Abstract][Full Text] [Related]
4. Human kallikrein hK2 has low kininogenase activity while prostate-specific antigen (hK3) has none. Deperthes D; Marceau F; Frenette G; Lazure C; Tremblay RR; Dubé JY Biochim Biophys Acta; 1997 Nov; 1343(1):102-6. PubMed ID: 9428664 [TBL] [Abstract][Full Text] [Related]
5. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors. Lövgren J; Airas K; Lilja H Eur J Biochem; 1999 Jun; 262(3):781-9. PubMed ID: 10411640 [TBL] [Abstract][Full Text] [Related]
6. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Mikolajczyk SD; Millar LS; Kumar A; Saedi MS Prostate; 1998 Jan; 34(1):44-50. PubMed ID: 9428387 [TBL] [Abstract][Full Text] [Related]
7. Specificity of human tissue kallikrein towards substrates containing Phe-Phe pair of amino acids. Pimenta DC; Chao J; Chao L; Juliano MA; Juliano L Biochem J; 1999 Apr; 339 ( Pt 2)(Pt 2):473-9. PubMed ID: 10191281 [TBL] [Abstract][Full Text] [Related]
8. Specificity of S'1 and S'2 subsites of human tissue kallikrein using the reactive-centre loop of kallistatin: the importance of P'1 and P'2 positions in design of inhibitors. Pimenta DC; Fogaça SE; Melo RL; Juliano L; Juliano MA Biochem J; 2003 May; 371(Pt 3):1021-5. PubMed ID: 12578561 [TBL] [Abstract][Full Text] [Related]
9. Differences in substrate and inhibitor sequence specificity of human, mouse and rat tissue kallikreins. Fogaça SE; Melo RL; Pimenta DC; Hosoi K; Juliano L; Juliano MA Biochem J; 2004 Jun; 380(Pt 3):775-81. PubMed ID: 15040788 [TBL] [Abstract][Full Text] [Related]
10. A positively charged loop on the surface of kallistatin functions to enhance tissue kallikrein inhibition by acting as a secondary binding site for kallikrein. Chen VC; Chao L; Chao J J Biol Chem; 2000 Dec; 275(51):40371-7. PubMed ID: 10991942 [TBL] [Abstract][Full Text] [Related]
11. Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. Zhou GX; Chao L; Chao J J Biol Chem; 1992 Dec; 267(36):25873-80. PubMed ID: 1334488 [TBL] [Abstract][Full Text] [Related]
12. Polyclonal and monoclonal antibodies to prostate-specific antigen can cross-react with human kallikrein 2 and human kallikrein 1. Finlay JA; Day JR; Rittenhouse HG Urology; 1999 Apr; 53(4):746-51. PubMed ID: 10197850 [TBL] [Abstract][Full Text] [Related]
13. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Lövgren J; Rajakoski K; Karp M; Lundwall â ; Lilja H Biochem Biophys Res Commun; 1997 Sep; 238(2):549-55. PubMed ID: 9299549 [TBL] [Abstract][Full Text] [Related]
14. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. Deperthes D; Frenette G; Brillard-Bourdet M; Bourgeois L; Gauthier F; Tremblay RR; Dubé JY J Androl; 1996; 17(6):659-65. PubMed ID: 9016396 [TBL] [Abstract][Full Text] [Related]
15. Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein. Chen VC; Chao L; Chao J J Biol Chem; 2000 Dec; 275(49):38457-66. PubMed ID: 10993887 [TBL] [Abstract][Full Text] [Related]
16. S(1)' and S(2)' subsite specificities of human plasma kallikrein and tissue kallikrein 1 for the hydrolysis of peptides derived from the bradykinin domain of human kininogen. Lima AR; Alves FM; Angelo PF; Andrade D; Blaber SI; Blaber M; Juliano L; Juliano MA Biol Chem; 2008 Dec; 389(12):1487-94. PubMed ID: 18844446 [TBL] [Abstract][Full Text] [Related]
17. Comparison of human and porcine tissue kallikrein substrate specificities. Del Nery E; Chagas JR; Juliano MA; Juliano L; Prado ES Immunopharmacology; 1999 Dec; 45(1-3):151-7. PubMed ID: 10615005 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of Kallikrein-Related Peptidases 7 and 5 by Grafting Serpin Reactive-Center Loop Sequences onto Sunflower Trypsin Inhibitor-1 (SFTI-1). Jendrny C; Beck-Sickinger AG Chembiochem; 2016 Apr; 17(8):719-26. PubMed ID: 26574674 [TBL] [Abstract][Full Text] [Related]
19. Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2. Mikolajczyk SD; Millar LS; Marker KM; Grauer LS; Goel A; Cass MM; Kumar A; Saedi MS Eur J Biochem; 1997 Jun; 246(2):440-6. PubMed ID: 9208936 [TBL] [Abstract][Full Text] [Related]
20. Substrate specificities of tissue kallikrein and T-kininogenase: their possible role in kininogen processing. Chagas JR; Hirata IY; Juliano MA; Xiong W; Wang C; Chao J; Juliano L; Prado ES Biochemistry; 1992 Jun; 31(21):4969-74. PubMed ID: 1599922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]